

Awards and Recognition

2010

- At the National Diversity Council's Inaugural Philadelphia Diversity and Leadership Conference, Cephalon EVP and Chief Medical Officer, Dr. Lesley Russell, MB.Ch.B., MRCP, was recognized as one of the "Most Powerful and Influential Women in Pennsylvania." Dr. Russell and eleven other professional women leaders were honored for achievements in their respective careers, their leadership excellence, their impact on their organizations in terms of performance and direction, and their commitment to the community. Dr. Russell was only individual from the pharmaceutical industry who was honored.
- Based on 2009 fiscal year revenue, Cephalon comes in ninth among pharmaceutical companies and 17 among public companies in the Philadelphia Business Journal's annual rankings. On the list of the fastest-growing public companies, Cephalon ties at the 9/10 spot, based on weighted growth score percentage—a combination of revenue and employee growth. The rankings were published in the journal's print editions and are compiled in its 2011 Book of Lists.
- Cephalon Chairman and CEO Frank Baldino, Jr., Ph.D., receives the 2010 Leadership Award for Outstanding Contributions to French-American Business Relations from the Philadelphia Chapter of the French-American Chamber of Commerce (FACC).
- On the *Fortune 1000* list, Cephalon ranks 781, compared to 903, which was the company's rank on the 2009 list. Based on revenues alone, the rankings include any companies incorporated in the U.S. for which revenues are publicly available.
- Cephalon ranks 14 among innovators in the quarterly Innovation Index of pharmaceutical and medical device industries by the stock research firms Innovaro Strategos and the wRatings Corporation. The Innovation Index, released May 2010, compares healthcare companies with those in food & beverage and consumer electronics.

2009

- The Chester County Chamber of Business & Industry recognizes Frank Baldino, Jr., Ph.D., for his contributions and service to the Chester County and Greater Philadelphia communities, and for his leadership in the pharmaceutical industry and to the company he founded 22 years ago. He is named 2009 CEO of the Year by the organization.
- In the 2009 *Pharmaceutical Executive* annual industry performance audit of publicly-traded pharmaceutical, biotechnology and generics companies, Cephalon ranks sixth of 27 based on an analysis of key 2007-2008 performance

metrics, including change in revenue and enterprise value, enterprise value to sales and profit to assets.

- For the second consecutive year, Cephalon is named one of America's best adoption-friendly workplaces by the Dave Thomas Foundation for Adoption. The list, determined by an analysis of adoption benefits available to employees, ranks Cephalon second among pharmaceutical companies and 36 among the top 100 companies.
- Cephalon is named to the 2009 *Fortune* list of America's 1,000 largest companies for the third consecutive year, rising in rank from 952 to 903 in the complete list of American's largest companies. In the list of the largest pharmaceutical companies, Cephalon ranks 20.
- For the second time, Cephalon was named to the *Forbes* listing of the Best Big Companies in America, based on factors that include sales and earnings growth, debt to total capital ratio, earnings outlook and stock market returns. Cephalon is one of just 14 companies in the drugs and biotechnology sector included in the 2008 listing.

2008

- The American Society for Clinical Oncology (ASCO) lists Cephalon oncology treatment TREANDA third of 12 major advances in cancer prevention and treatment in 2008. Only studies that significantly altered the way a cancer is understood, or had an important impact on patient care, are included in the list.
- Cephalon ranks 17 in *Automotive Fleet* magazine's Top 50 Hybrid Fleet list of commercial fleets, recognizing a corporate initiative designed to increase fuel efficiency, and reduce the carbon footprint and greenhouse gas emissions.
- Standard & Poor's adds Cephalon to the world-renowned S&P 500 Index. The Index represents the top 500 companies in leading industries of the U.S. economy. The S&P 500 is widely regarded as the best single gauge of the U.S. equities market.
- The Utah Technology Council 2008 Hall Of Fame inducts Dr. Theodore H. Stanley, who, in 1985 commercialized his 1983 product invention, ACTIQ® (oral transmucosal fentanyl citrate) C-II; ACTIQ became the first pain product marketed by Cephalon.
- Cephalon is included in the new NASDAQ OMX Biotechnology Index (NASDAQ:QGBI), a modified market-capitalization weighted index designed to track the performance of the largest and most liquid companies engaged in the biotechnology sector.
- Cephalon receives the AmerisourceBergen Manufacturer of the Year Award, Branded Pharmaceutical Sales Under \$300 Million, for the second consecutive year.
- Cephalon is named to the 2008 Dave Thomas Foundation for Adoption list of America's Top 100 employers with the best adoption benefits, ranking third among pharmaceutical companies, and 26 out of the top 100 employers with the best adoption benefits.
- Eric Floyd, Cephalon Vice President of Worldwide Regulatory Affairs, is named by *Pharmaceutical Executive* as one of their "45 under 45" Emerging Leaders.
- Robert P. Roche, Jr., Cephalon Executive Vice President, Worldwide Pharmaceutical

Operations, receives the Man of the Year Award from the Greater Philadelphia Chapter of the Leukemia & Lymphoma Society for spearheading the effort to raise funds for blood cancer research, education and patient services.

- Cephalon Europe President Alain Aragues is named a Chevalier of the Légion d'Honneur by the government of France in recognition of his contributions to the country, particularly his tireless efforts to improve healthcare standards for people suffering with HIV and his impressive record in creating jobs in the pharmaceutical industry. Since joining Cephalon in 2002, Alain has led the company's expansion throughout Europe.

2007

- Deloitte & Touche USA LLP names Cephalon to the 2007 Greater Philadelphia Technology Fast 50, which recognizes the 50 fastest growing technology, media, telecommunication and life sciences companies in the Greater Philadelphia area based on percentage revenue growth over five years.
- Cephalon is awarded the 2007 British American Business Council Explorer Award, given annually to a company in the greater Philadelphia region that has made a significant business investment in the United Kingdom.
- Cephalon CEO Frank Baldino, Jr., Ph.D., is named by *PharmaVOICE* as one of the "100 Most Inspiring People" and included in a list of entrepreneurs who are redefining the life-sciences industry through innovative approaches to improving technologies, processes, services and ultimately patient care.
- Cephalon is added to the NASDAQ-100 Index, which includes 100 of the largest non-financial domestic and international securities listed on the NASDAQ Stock Market based on market capitalization.
- Cephalon joins the list of companies included in *Fortune's* annual ranking of America's 1,000 largest corporations. Cephalon is one of only 19 companies in the pharmaceutical sector to make *Fortune's* list in 2007.
- The World Economic Forum inducts Cephalon into its "Community of Global Growth Companies" — a group of companies with revenues of \$100 million to \$2 billion, annual growth of more than 15%, a focus on global expansion strategies and demonstrated leadership in a particular industry.
- *R&D Directions* magazine identifies Cephalon compounds CEP-701 (lestaurtinib) for the treatment of acute myeloid leukemia, and TREANDA® (bendamustine HCl) for the treatment of nonHodgkin's lymphoma, as two of the 100 Great Investigational Drugs of 2007.
- *Industry Week* ranks Cephalon as one of the 500 largest U.S. manufacturers in its annual reporting of the largest publicly held U.S. manufacturing companies based on revenue. Cephalon moves up from 458 in the 2006 ranking to 381 in 2007.

2006

- Frank Baldino, Jr., Ph.D., is honored by the World Trade Center of Greater Philadelphia for his contributions to regional economic development.

- Dr. Baldino receives the first Hubert J.P. Schoemaker Leadership Award, which recognizes a leader in the biosciences community who best exemplifies the spirit of innovation in the Commonwealth of Pennsylvania.
- Cephalon wins the 2006 Supplier of the Year Award in the midsize brand pharmaceutical category by McKesson Corporation.
- Cephalon ranks among the top 40 companies in *The Scientist* magazine's "Best Places to Work in Industry" survey.

2005

- Cephalon co-sponsors BIO 2005, which attracts 18,000 people from 50 countries to the Greater Philadelphia Region. Cephalon advertising at AMTRAK's 30th Street Station in Philadelphia was seen by the 18,000 attendees and general public.
- Cephalon is named for the third consecutive year to the Deloitte & Touche Technology Fast 500, which recognizes the fastest-growing technology companies in the U.S. and Canada.
- Cephalon receives the HD Smith Wholesale Drug Company Vendor of the Year award and the Cardinal Health Supplier Quality Award for superior quality of service.
- The Boy Scouts of America Cradle of Liberty Council honor Frank Baldino, Jr., Ph.D., with the technology "Good Scout" award.
- Cephalon is ranked the sixth most admired biotechnology company by *MedAdNews*, a monthly magazine that covers marketing in the pharmaceutical business.

2004

- Cephalon is named among worldwide biotechnology companies ranked by percentage of total revenue devoted to R&D in *Leaders of Life Science* magazine.
- Frank Baldino, Jr., Ph.D., is honored with the Chester County Economic Development Council's Hall of Fame Award for outstanding achievements.
- Cephalon is named to the 2004 edition of *Forbes 2000*, a comprehensive list of the world's biggest and most powerful companies.
- PROVIGIL® (modafinil) Tablets [C-IV] is listed by Drug Topics as 113 among the top 200 branded drugs in 2003, measured by retail dollars spent on prescriptions.
- Harvard Medical School Endowed Chair is named after Frank Baldino, Jr., Ph.D.
- Cephalon is ranked by *MedAdNews* in the "Top 10 Biotechnology Companies" list based on total revenues.
- Cephalon is included in *Fortune 40—A Model Portfolio with the Best Investment Ideas for the Year Ahead*.
- Cephalon is named for the second consecutive year to the Deloitte & Touche Technology Fast 50 and the Fast 500 lists based on percentage of revenue growth over five years.

2003

- Cephalon is named to the *Forbes 500* list, a report card on how the biggest and most profitable companies perform.
- Cephalon is included in the *Forbes* list of Fastest Growing Technology Companies.
- Cephalon is ranked among the top 10 “Most Admired Biotechnology Companies” by *MedAdNews*.
- Cephalon is inducted into the Biotech Hall of Fame in the Best of Biotech 2003 Awards.
- The Great Valley Chamber of Commerce names Cephalon the “Entrepreneurial Company of the Year.”
- Cephalon is named to the Deloitte & Touche Technology Fast 50 and the Fast 500 lists based on percentage of revenue growth over five years.
- *The Scientist* magazine ranks Cephalon as one of the “Top 10 Best Places to Work.”
- Cephalon is selected to join the NASDAQ 100.
- Cephalon receives the Deloitte & Touche Technology Fast 50 award as one of the fifty fastest-growing companies in America.
- Cephalon receives the National Sleep Foundation Corporate Award for work in sleep medicine.
- Cephalon is recognized by Invest in France Agency and the French-American Chamber of Commerce.
- Cephalon is honored by the Eastern Technology Council as Life Science Company of the Year.